medigraphic.com

2006, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (3)

Prevalence of Hepatitis C Virus in the Blood Bank at Centro Médico Nacional La Raza

Benítez-Arvizu G, Cortez-Gómez R, Novelo-Garza BA, Malagón-Martínez A, Guerra-Márquez A, Alvarado-Maldonado MC, Rodríguez-Bartolo M, Argüelles-Pimentel RM, Sánchez-Barrera RG

Language: Spanish
References: 29
Page: 227-233
PDF size: 103.07 Kb.


ABSTRACT

Introduction: There are no records on the prevalence of infection by HCV in Mexican population. The central area of Mexico is a highly dense demographic zone and is the influence area of the second blood bank in Latin America in terms of affluence.
Material and methods: We prospectively studied the prevalence and genotypes of HCV infection in 5105 individuals attending the Central Blood Bank of Centro Médico Nacional La Raza regardless if they were accepted or rejected as donors. We applied a quimiolumiscence assay as a screening test. A recombinant immunoassay (RIBA) and a qualitative polymerase chain reaction (PCR) were performed as confirmatory tests and to detect viremia, respectively. Virus genotype was identified by means of a Line Immuno Probe Assay in PCR positive samples.
Results: The overall prevalence of HCV infection was 0.195 % (10/5105). Viremia was detected in 90 % of the subjects. The prevalence of accepted donors (0.087 %) was significantly lower (p = 0.017) than that of the rejected ones (0.421 %). Among viremic subjects, 60 % were infected with genotype 2 and 40 % with a subtype combination (a/b) of genotype 1.
Discussion: The prevalence of HCV infection in our population was significantly lower than the world mean prevalence estimated in 3 %. A higher prevalence of genotype 2 in asymptomatic individuals contrasts with previous studies with a selected population where genotype 1 prevailed.


REFERENCES

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDna clone derived from a blood-borne non-a non-b viral hepatitis genome. Science 1989;244:359-362.

  2. Simmonds P, Holmes EC, Cha TA, Chan SW, Mc Omish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399.

  3. Robertson B, Myers G, Howard C. Classification, nomenclature, and database development for hepa-titis C virus (HCV) and related viruses. Proposes for standardization. Arch Virol 1998;143:2493-2503.

  4. Pardrat P, Trepo C. HCV: Epidemiology, modes of transmission and prevention of spread. Bailliére’s Clin Gastroenterol 2000;14:201-210.

  5. Memon MI, Memon MA. Hepatitis C. An epide-miological review. J Viral Hepatitis 2002;9:84-100.

  6. Hammer GH, Kellogg TA, McFarland WC, Wong E, Louie B, Williams I, et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997–2000. Sex Transm Dis 2003; 30:919-924.

  7. Flamm SL, Lovinger S. Chronic hepatitis C virus infection. JAMA 2003;289:2413-2417.

  8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.

  9. Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678.

  10. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-235.

  11. Gary LD. Hepatitis C virus genotypes and quasi-species. Am J Med 1999;Suppl 6B:S21-S26.

  12. Navarro-Hernández RE, Ramírez-Barragán J, Muñoz-Valle JF. Seroprevalencia de anticuerpos IgG contra el virus de la hepatitis C en dos bancos de sangre de dos hospitales regionales de la Secretaría de Salud, Jalisco. Rev Mex Patol Clin 1999;46:166-171.

  13. Guerrero-Romero JF, Castañeda A, Rodríguez-Morán M. Prevalence of risk factors associated with hepatitis C in blood donors in the municipality of Durango, Mexico. Salud Publica Mex 1996; 38:94-100.

  14. Hernández-Pérez RE, Frías-Salcedo JA, Del Ángel-Guevara O. Seroprevalence of antibodies against the hepatitis C virus in blood donors at the Hos-pital Central Militar. Salud Publica Mex 1994;36: 538-540.

  15. Méndez-Sánchez N, Motola-Kuba D, Chávez-Tapia NC, Bahena J, Correa-Rotter, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004;42: 4321-4322.

  16. Kuo G, Choo Q, Alter HJ. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989;244:362-364.

  17. Miyamura T, Saito I, Katayama T. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA. Application to diagnosis and blood screening for postransfusion hepa-titis. Proc Natl Acad Sci USA 1990;87:983-987.

  18. Aach RD, Stevens CE, Hollinger FB. Hepatitis C virus infection in post transfusion hepatitis: an analysis with first and second generation assays. N Engl J Med 1991;325:1325-1329.

  19. Tobler LH, Stramer SL, Lee SR, Masecar BL, Peterson JE, Davis EA, et al. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. Transfusion 2003;43:1452-1459.

  20. Feucht HH, Zôllner B, Polywka S, Laufs R. Study on reliability of commercially available hepatitis C virus antibody tests. J Clin Microbiol 1995;33: 620-624.

  21. Center for Disease Control. Prevention guidelines for laboratory testing and result reporting of anti-body to hepatitis C virus. MMWR 2003;52(RR-3):1-15.

  22. Nolte FS, Fried MW, Shiffman ML, Ferreira-González A, Garrett CT, Schiff ER, et al. Pros-pective multicenter clinical evaluation of Amplicor and cobas Amplicor hepatitis C virus tests. J Clin Microbiol 2001;39:4005-4012.

  23. Lee SC, Antony A, Lee N, Leibrow J, Yang JQ, Soviero S, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000;38:4171-4179.

  24. Mukaide M, Tanaka Y, Kakuda H, Fujiwara K, Kurbanov F, Orito E, et al. New combination test for hepatitis C virus genotype and viral load deter-mination using Amplicor GT HCV Monitor test v2.0. World J Gastroenterol 2005;11:469-475.

  25. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, VanHeuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.

  26. Stuyver L, Wyseur A, Van Arnhem W, Hernández F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34:2259-66.

  27. Resano-Pérez E, Méndez-Ramírez I, Shamah-Levy T, Rivera JA, Sepúlveda-Amor J. Metodología de la Encuesta Nacional de Salud 1999. Salud Publica Mex 2003;45(Suppl 4):S558-S564.

  28. Alter MJ, Kruszon-Morán D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.

  29. Marín y López RA, Romero-Estrella S, Infante-Ramírez L, Méndez-Aquino JS, Berrón-Ruiz P, Morales-Alfaro NA, et al. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form. Transfusion 2004;44:1344-1349.




2020     |     www.medigraphic.com